Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/28214
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gurgula, O | - |
dc.contributor.editor | Bonadio, E | - |
dc.contributor.editor | Shemtov, N | - |
dc.date.accessioned | 2024-02-05T10:14:19Z | - |
dc.date.available | 2024-02-05T10:14:19Z | - |
dc.date.issued | 2024 | - |
dc.identifier | ORCID iD: Olga Gurgula https://orcid.org/0000-0002-7013-9804 | - |
dc.identifier.citation | Gurgula, O. (2024) 'Patenting Strategies by Pharmaceutical Companies: A Lawful Use of the Patent System or an Abusive Conduct?', in Bonadio, E. and Shemtov, N. (eds.) A Research Agenda for Patent Law, Cheltenham: Edward Elgar, (forthcoming), pp. 1 - [24]. | en_US |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/28214 | - |
dc.description | A preprint of this forthcoming book chapter in Bonadio and Shemtov (ed), ‘A Research Agenda for Patent Law’, Edward Elgar, is available at SSRN: https://ssrn.com/abstract=4591250 or https://doi.org/10.2139/ssrn.4591250. It has not been certified by peer review. | - |
dc.description.abstract | To delay generic competition, pharmaceutical companies have been increasingly relying on the patent system. Some of their patent-related practices, such as pay-for-delay agreements, have attracted significant attention of competition authorities in several jurisdictions. However, other practices remain outside of competition authorities’ investigative activities in most jurisdictions, including in Europe. This chapter will discuss two strategies that are employed by pharmaceutical companies to prevent generic competition, namely: (a) strategic accumulation of patents and (b) product hopping. These strategies have the capacity to produce negative effects on the market by delaying market entry of cheaper generics and resulting in a substantial additional cost to the public. The main aim of this chapter is, therefore, to attract attention of policy makers world-wide to these practices explaining their essence, anticompetitive nature and effects. | en_US |
dc.format.extent | 1 - 24 | - |
dc.language.iso | en | en_US |
dc.publisher | Edward Elgar | en_US |
dc.rights | Copyright © 2024 The Author. This is a draft chapter/article. The final version will be available in A Research Agenda for Patent Law, edited by Eduardo Bonadio and Noam Shemtov, forthcoming 2024, Edward Elgar Publishing Ltd. The material cannot be used for any other purpose without further permission of the publisher, and is for private use only (see: https://www.e-elgar.com/author-hub/reuse-of-your-work/). | - |
dc.rights.uri | https://www.e-elgar.com/author-hub/reuse-of-your-work/ | - |
dc.title | Patenting Strategies by Pharmaceutical Companies: A Lawful Use of the Patent System or an Abusive Conduct? | en_US |
dc.type | Book chapter | en_US |
dc.relation.isPartOf | A Research Agenda for Patent Law | - |
pubs.place-of-publication | UK | - |
pubs.publication-status | Accepted | - |
dc.rights.holder | The Author | - |
Appears in Collections: | Brunel Law School Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2024 The Author. This is a draft chapter/article. The final version will be available in A Research Agenda for Patent Law, edited by Eduardo Bonadio and Noam Shemtov, forthcoming 2024, Edward Elgar Publishing Ltd. The material cannot be used for any other purpose without further permission of the publisher, and is for private use only (see: https://www.e-elgar.com/author-hub/reuse-of-your-work/). | 570.9 kB | Adobe PDF | View/Open |
Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.